242 related articles for article (PubMed ID: 19931261)
1. An Msh2 conditional knockout mouse for studying intestinal cancer and testing anticancer agents.
Kucherlapati MH; Lee K; Nguyen AA; Clark AB; Hou H; Rosulek A; Li H; Yang K; Fan K; Lipkin M; Bronson RT; Jelicks L; Kunkel TA; Kucherlapati R; Edelmann W
Gastroenterology; 2010 Mar; 138(3):993-1002.e1. PubMed ID: 19931261
[TBL] [Abstract][Full Text] [Related]
2. Temozolomide increases the number of mismatch repair-deficient intestinal crypts and accelerates tumorigenesis in a mouse model of Lynch syndrome.
Wojciechowicz K; Cantelli E; Van Gerwen B; Plug M; Van Der Wal A; Delzenne-Goette E; Song JY; De Vries S; Dekker M; Te Riele H
Gastroenterology; 2014 Nov; 147(5):1064-72.e5. PubMed ID: 25088490
[TBL] [Abstract][Full Text] [Related]
3. A knockout for Lynch syndrome.
Boland CR
Gastroenterology; 2010 Mar; 138(3):820-2. PubMed ID: 20102757
[No Abstract] [Full Text] [Related]
4. Mesalazine and thymoquinone attenuate intestinal tumour development in Msh2(loxP/loxP) Villin-Cre mice.
Kortüm B; Campregher C; Lang M; Khare V; Pinter M; Evstatiev R; Schmid G; Mittlböck M; Scharl T; Kucherlapati MH; Edelmann W; Gasche C
Gut; 2015 Dec; 64(12):1905-12. PubMed ID: 25429050
[TBL] [Abstract][Full Text] [Related]
5. The Transcriptomic Landscape of Mismatch Repair-Deficient Intestinal Stem Cells.
Bommi PV; Bowen CM; Reyes-Uribe L; Wu W; Katayama H; Rocha P; Parra ER; Francisco-Cruz A; Ozcan Z; Tosti E; Willis JA; Wu H; Taggart MW; Burks JK; Lynch PM; Edelmann W; Scheet PA; Wistuba II; Sinha KM; Hanash SM; Vilar E
Cancer Res; 2021 May; 81(10):2760-2773. PubMed ID: 34003775
[TBL] [Abstract][Full Text] [Related]
6. Loss of MMR and TGFBR2 Increases the Susceptibility to Microbiota-Dependent Inflammation-Associated Colon Cancer.
Tosti E; Almeida AS; Tran TTT; Barbachan E Silva M; Broin PÓ; Dubin R; Chen K; Beck AP; Mclellan AS; Vilar E; Golden A; O'Toole PW; Edelmann W
Cell Mol Gastroenterol Hepatol; 2022; 14(3):693-717. PubMed ID: 35688320
[TBL] [Abstract][Full Text] [Related]
7. Recurrent Frameshift Neoantigen Vaccine Elicits Protective Immunity With Reduced Tumor Burden and Improved Overall Survival in a Lynch Syndrome Mouse Model.
Gebert J; Gelincik O; Oezcan-Wahlbrink M; Marshall JD; Hernandez-Sanchez A; Urban K; Long M; Cortes E; Tosti E; Katzenmaier EM; Song Y; Elsaadi A; Deng N; Vilar E; Fuchs V; Nelius N; Yuan YP; Ahadova A; Sei S; Shoemaker RH; Umar A; Wei L; Liu S; Bork P; Edelmann W; von Knebel Doeberitz M; Lipkin SM; Kloor M
Gastroenterology; 2021 Oct; 161(4):1288-1302.e13. PubMed ID: 34224739
[TBL] [Abstract][Full Text] [Related]
8. Associations of Pathogenic Variants in MLH1, MSH2, and MSH6 With Risk of Colorectal Adenomas and Tumors and With Somatic Mutations in Patients With Lynch Syndrome.
Engel C; Ahadova A; Seppälä TT; Aretz S; Bigirwamungu-Bargeman M; Bläker H; Bucksch K; Büttner R; de Vos Tot Nederveen Cappel WT; Endris V; Holinski-Feder E; Holzapfel S; Hüneburg R; Jacobs MAJM; Koornstra JJ; Langers AM; Lepistö A; Morak M; Möslein G; Peltomäki P; Pylvänäinen K; Rahner N; Renkonen-Sinisalo L; Schulmann K; Steinke-Lange V; Stenzinger A; Strassburg CP; van de Meeberg PC; van Kouwen M; van Leerdam M; Vangala DB; Vecht J; Verhulst ML; von Knebel Doeberitz M; Weitz J; Zachariae S; Loeffler M; Mecklin JP; Kloor M; Vasen HF; ;
Gastroenterology; 2020 Apr; 158(5):1326-1333. PubMed ID: 31926173
[TBL] [Abstract][Full Text] [Related]
9. Reduced mRNA expression in paraffin-embedded tissue identifies MLH1- and MSH2-deficient colorectal tumours and potential mutation carriers.
Müller A; Zielinski D; Friedrichs N; Oberschmid B; Merkelbach-Bruse S; Schackert HK; Linnebacher M; von Knebel Doeberitz M; Büttner R; Rüschoff J;
Virchows Arch; 2008 Jul; 453(1):9-16. PubMed ID: 18581137
[TBL] [Abstract][Full Text] [Related]
10. Mouse models for hereditary nonpolyposis colorectal cancer.
de Wind N; Dekker M; van Rossum A; van der Valk M; te Riele H
Cancer Res; 1998 Jan; 58(2):248-55. PubMed ID: 9443401
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of mismatch repair-deficient crypt foci in Lynch syndrome: a pathological study.
Kloor M; Huth C; Voigt AY; Benner A; Schirmacher P; von Knebel Doeberitz M; Bläker H
Lancet Oncol; 2012 Jun; 13(6):598-606. PubMed ID: 22552011
[TBL] [Abstract][Full Text] [Related]
12. MSH2 deficiency contributes to accelerated APC-mediated intestinal tumorigenesis.
Reitmair AH; Cai JC; Bjerknes M; Redston M; Cheng H; Pind MT; Hay K; Mitri A; Bapat BV; Mak TW; Gallinger S
Cancer Res; 1996 Jul; 56(13):2922-6. PubMed ID: 8674041
[TBL] [Abstract][Full Text] [Related]
13. Stromal Indian hedgehog signaling is required for intestinal adenoma formation in mice.
Büller NV; Rosekrans SL; Metcalfe C; Heijmans J; van Dop WA; Fessler E; Jansen M; Ahn C; Vermeulen JL; Westendorp BF; Robanus-Maandag EC; Offerhaus GJ; Medema JP; D'Haens GR; Wildenberg ME; de Sauvage FJ; Muncan V; van den Brink GR
Gastroenterology; 2015 Jan; 148(1):170-180.e6. PubMed ID: 25307863
[TBL] [Abstract][Full Text] [Related]
14. Conditional expression of mutated K-ras accelerates intestinal tumorigenesis in Msh2-deficient mice.
Luo F; Brooks DG; Ye H; Hamoudi R; Poulogiannis G; Patek CE; Winton DJ; Arends MJ
Oncogene; 2007 Jun; 26(30):4415-27. PubMed ID: 17297472
[TBL] [Abstract][Full Text] [Related]
15. Diagnosis of Constitutional Mismatch Repair-Deficiency Syndrome Based on Microsatellite Instability and Lymphocyte Tolerance to Methylating Agents.
Bodo S; Colas C; Buhard O; Collura A; Tinat J; Lavoine N; Guilloux A; Chalastanis A; Lafitte P; Coulet F; Buisine MP; Ilencikova D; Ruiz-Ponte C; Kinzel M; Grandjouan S; Brems H; Lejeune S; Blanché H; Wang Q; Caron O; Cabaret O; Svrcek M; Vidaud D; Parfait B; Verloes A; Knappe UJ; Soubrier F; Mortemousque I; Leis A; Auclair-Perrossier J; Frébourg T; Fléjou JF; Entz-Werle N; Leclerc J; Malka D; Cohen-Haguenauer O; Goldberg Y; Gerdes AM; Fedhila F; Mathieu-Dramard M; Hamelin R; Wafaa B; Gauthier-Villars M; Bourdeaut F; Sheridan E; Vasen H; Brugières L; Wimmer K; Muleris M; Duval A;
Gastroenterology; 2015 Oct; 149(4):1017-29.e3. PubMed ID: 26116798
[TBL] [Abstract][Full Text] [Related]
16. Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy.
Kim ST; Lee J; Park SH; Park JO; Lim HY; Kang WK; Kim JY; Kim YH; Chang DK; Rhee PL; Kim DS; Yun H; Cho YB; Kim HC; Yun SH; Lee WY; Chun HK; Park YS
Cancer Chemother Pharmacol; 2010 Sep; 66(4):659-67. PubMed ID: 20033812
[TBL] [Abstract][Full Text] [Related]
17. The effect of DNA mismatch repair (MMR) status on oxaliplatin-based first-line chemotherapy as in recurrent or metastatic colon cancer.
Kim ST; Lee J; Park SH; Park JO; Lim HY; Kang WK; Kim JY; Kim YH; Chang DK; Rhee PL; Kim DS; Yun H; Cho YB; Kim HC; Yun SH; Chun HK; Lee WY; Park YS
Med Oncol; 2010 Dec; 27(4):1277-85. PubMed ID: 19949897
[TBL] [Abstract][Full Text] [Related]
18. Non-Hodgkin lymphoma related to hereditary nonpolyposis colorectal cancer in a patient with a novel heterozygous complex deletion in the MSH2 gene.
Pineda M; Castellsagué E; Musulén E; Llort G; Frebourg T; Baert-Desurmont S; González S; Capellá G; Blanco I
Genes Chromosomes Cancer; 2008 Apr; 47(4):326-32. PubMed ID: 18181177
[TBL] [Abstract][Full Text] [Related]
19. Microsatellite instability and expression of MLH1 and MSH2 in carcinomas of the small intestine.
Planck M; Ericson K; Piotrowska Z; Halvarsson B; Rambech E; Nilbert M
Cancer; 2003 Mar; 97(6):1551-7. PubMed ID: 12627520
[TBL] [Abstract][Full Text] [Related]
20. Mutator phenotype in Msh2-deficient murine embryonic fibroblasts.
Reitmair AH; Risley R; Bristow RG; Wilson T; Ganesh A; Jang A; Peacock J; Benchimol S; Hill RP; Mak TW; Fishel R; Meuth M
Cancer Res; 1997 Sep; 57(17):3765-71. PubMed ID: 9288785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
